The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
1/50 - 1/100.
Use at an assay dependent concentration. PubMed: 22331196
FunctionOn ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Receptor for activin. May be involved for left-right pattern formation during embryogenesis.
Tissue specificityExpressed in normal parenchymal cells, endothelial cells, fibroblasts and tumor-derived epithelial cells.
Involvement in diseaseDefects in ACVR1 are a cause of fibrodysplasia ossificans progressiva (FOP) [MIM:135100]. FOP is a rare autosomal dominant disorder of skeletal malformations and progressive extraskeletal ossification. Heterotopic ossification in FOP begins in childhood and can be induced by trauma or may occur without warning. Bone formation is episodic and progressive, leading to extra-articular ankylosis of all major joints of the axial and appendicular skeleton, rendering movement impossible.
Sequence similaritiesBelongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family. TGFB receptor subfamily. Contains 1 GS domain. Contains 1 protein kinase domain.
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Activin Receptor Type IA antibody (ab60157)
ab60157, at a 1/50-1/100 dilution, staining Activin Receptor Type IA in human hepatocarcinoma on Formalin fixed Paraffin embedded tissue. A peroxidase-conjugated secondary antibody was used, followed by AEC staining.
References for Anti-Activin Receptor Type IA antibody (ab60157)
This product has been referenced in:
Townsend KL et al. Bone morphogenetic protein 7 (BMP7) reverses obesity and regulates appetite through a central mTOR pathway. FASEB J26:2187-96 (2012).
Read more (PubMed: 22331196) »